Global Neuromyelitis Optica Drug Market Growth (Status and Outlook) 2023-2029

Global Neuromyelitis Optica Drug Market Growth (Status and Outlook) 2023-2029

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

LPI (LP Information)' newest research report, the “Neuromyelitis Optica Drug Industry Forecast” looks at past sales and reviews total world Neuromyelitis Optica Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Neuromyelitis Optica Drug sales for 2023 through 2029. With Neuromyelitis Optica Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neuromyelitis Optica Drug industry.

This Insight Report provides a comprehensive analysis of the global Neuromyelitis Optica Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neuromyelitis Optica Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neuromyelitis Optica Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neuromyelitis Optica Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neuromyelitis Optica Drug.

The global Neuromyelitis Optica Drug market size is projected to grow from US$ 46 million in 2022 to US$ 57 million in 2029; it is expected to grow at a CAGR of 3.1% from 2023 to 2029.

Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.

This report presents a comprehensive overview, market shares, and growth opportunities of Neuromyelitis Optica Drug market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Glucocorticoids

Immunotherapies

Others

Segmentation by application

Acute Attack

Remission Prophylactic Treatment

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Pfizer

Fresenius

Teva

Sandoz

Intas

Gyjtrs

NANG KUANG

Tianjin Kingyork

Baxter

CSL

Grifols

Octapharma

CBOP

Please note: The report will take approximately 2 business days to prepare and deliver.